Clinical Trial

Biomarkers to Detect Endocrine Therapy Resistance

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-09-27; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Recruiting 2023-10-10
Trial Details
NCT Number NCT06067503
Lead Sponsor University of Wisconsin, Madison
Conditions Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Enrollment 8 participants
Start Date 2024-04-30
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-13